scholarly journals Complete scrotal urinary bladder hernia with both ureters and small intestine presenting as dysuria, bilateral ureterohydronephrosis, and acute renal insufficiency

2013 ◽  
Vol 114 (11) ◽  
pp. 642-644
Author(s):  
V. Nagy ◽  
I. Kilar
Keyword(s):  
Small Intestine ◽  
Urinary Bladder ◽  
Renal Insufficiency ◽  
Bladder Hernia ◽  
Acute Renal Insufficiency

Urinary bladder hernia

2021 ◽  
Author(s):  
Mostafa El-Feky
Keyword(s):  
Urinary Bladder ◽  
Bladder Hernia

Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 2518-2518
Author(s):  
Thorsten Oliver Goetze ◽  
Daniel Wilhelm Mueller ◽  
Mohammad-Reza Rafiyan ◽  
Dragan Kiselicki ◽  
Timursah Habibzade ◽  
...  
Keyword(s):  
Adverse Events ◽  
Renal Insufficiency ◽  
Diffuse Myocardial Fibrosis ◽  
Pleural Mesothelioma ◽  
Advanced Solid Tumors ◽  
Clinical Progression ◽  
Grade 5 ◽  
Common Grade ◽  
Acute Renal Insufficiency ◽  
Grade 3

2518 Background: Stratum D of the INSIGHT platform trial evaluates s.c. eftilagimod alpha (efti, IMP321) combined with avelumab in advanced solid tumors. Efti is an MHC class II agonist which activates antigen-presenting cells followed by CD8 T-cell activation. Combination with PD-1/PD-L1 blockade aims at enhanced efficacy. Methods: This IIT platform trial consists of 5 strata: intratumoral (A) or intraperitoneal efti (B); s.c. efti with SOC (C) or with PD-L1 inhibition (D). Strat E is currently under development and starts soon with a new efti combination. This abstract focuses on preliminary data of Strat D. Patients (pts) received 800mg avelumab i.v. q2w along with s.c. efti: 6mg in cohort 1 (coh 1, 6 pts), 30mg in cohort 2 (coh 2, 6 pts). Primary endpoint: safety. Results: Recruitment has been completed with 12 pts (coh 1: gastric, gallbladder, colon cancer, pleural mesothelioma; coh 2: gastric, gastroesophageal, anal, rectum, cervix uteri). No dose limiting toxicities (DLTs) occurred. 10 serious adverse events (SAEs) were reported, none of them considered causally related (4 in 3 pts of coh 1 [1 acute renal insufficiency grade 5 in 1 pt, 2 preileus grade 3 in 1 pt, hearing impaired grade 4 in 1 pt] and 6 in 4 pts of coh 2 [1 anal hemorrhage and 1 gallbladder obstruction in 1 pt, 1 eye pain and 1 surgery to replace the feeding tube in 1 pt, each grade 3, 1 skin infection grade 2, 1 diffuse myocardial fibrosis grade 5]. 1 AE of special interest (AESI) possibly related with avelumab (sarcoidosis grade 1) occurred in coh 1. 2 pts completed max treatment duration with 24 cycles. In coh 1, 47 adverse events (AEs; grade 1-2, 29; grade 3, 14; grade 4, 3; grade 5, 1) occurred in 5 pts. Most common grade 1-2 AEs were nausea, pain in 33%, 33% of the pts. Most common grade 3 AEs were ileus, vomiting in 33%, 33% of the pts. 2 AEs grade 4 (hearing impaired, sepsis) and 1 AE grade 5 (acute renal insufficiency) were reported. All AEs grade 3-5 were considered causally unrelated. In coh 2, 51 adverse events (AEs; grade 1-2, 29; grade 3, 19; grade 4, 2; grade 5, 1) occurred in 5 pts. The most common grade 1-2 AE was hypothyroidism in 33% of the pts. 1 AE grade 5 (diffuse myocardial fibrosis) was reported. Only 1 AE grade 3-5 was considered causally related (urinary tract infection grade 3 related with avelumab). 5 pts showed partial response as best response (2 coh 1: colon, pleural mesothelioma; 3 coh 2: gastric, anal, cervical), 1 stable disease with clinical progression (coh 2) (all but one of these pts still alive), 5 disease progressions acc. to RECIST 1.1 (3 coh 1, 2 coh 2), 1 clinical progression (coh 1). Signals of activity were also observed in pre-treated MSS/PD-L1low pts. Conclusions: Combined treatment with avelumab 800mg and efti 6mg (coh 1) or 30 mg efti (coh 2) seems feasible and safe. No unexpected AEs occurred. Signals of efficacy with CPI combination were seen (DCR 50%). Clinical trial information: NCT03252938.

Acute Renal Insufficiency Due to Oral Acyclovir in a Man With Sickle Cell Trait

1999 ◽  
Vol 92 (11) ◽  
pp. 1093-1094 ◽  
Author(s):  
ANTHONY F. LAWSON ◽  
PHILLIP A. GREEN ◽  
ALLAN S. BRETT
Keyword(s):  
Renal Insufficiency ◽  
Sickle Cell ◽  
Sickle Cell Trait ◽  
Oral Acyclovir ◽  
Acute Renal Insufficiency

Urinary bladder hernia: an unusual presentation of abdominal pain

2010 ◽  
Vol 27 (6) ◽  
pp. 489-489 ◽  
Author(s):  
W.-Y. Kuo ◽  
T.-Y. Lin ◽  
W.-J. Lee
Keyword(s):  
Abdominal Pain ◽  
Urinary Bladder ◽  
Unusual Presentation ◽  
Bladder Hernia

scholarly journals Application of Fasudil in the Treatment of Contrast-Induced Acute Renal Insufficiency Based on Computerized Tomography Intelligent information monitoring (Preprint)

2020 ◽  
Author(s):  
Xiuming Zhang ◽  
Tao Liu ◽  
Chunhua Tian ◽  
Lucien Herbert
Keyword(s):  
Renal Insufficiency ◽  
Renal Disease ◽  
Contrast Agent ◽  
Computerized Tomography ◽  
Disease Model ◽  
Control Group ◽  
Model Group ◽  
High Group ◽  
Acute Renal Insufficiency ◽  
Intelligent Information

BACKGROUND Background: Contrast-induced acute kidney injury (CI-AKI) is one of the main causes of hospital-acquired acute kidney failure. At present, the exact pathogenesis of CI-AKI is not yet clear. However, the contrast agent reduces renal blood flow and filtration rate, which is its direct toxic effect on renal tubules. Fasudil can relax vascular smooth muscle and act on the kidney, which has a very obvious effect on the expansion of the renal arterioles; also, by adjusting the vascular tone of the microcirculation before and after the glomerulus, it can regulate renal hemodynamics. OBJECTIVE Objective: The objective was to explore the application of Fasudil in the treatment of contrast-induced acute renal insufficiency based on computerized tomography intelligent information monitoring, and explore the application of single-photon emission computerized tomography (SPECT) in the diagnosis of renal insufficiency. METHODS Methods: 32 BALB/C mice were randomly divided into 4 groups, i.e., the renal disease model group (the model group), the renal disease model plus Fasudil high dosage group (the Fasudil high group), the renal disease model plus Fasudil low dosage group (the Fasudil low group), and the control group. After the mice models were grouped, they were banned from drinking water for 12 h. Mice in the model group, the Fasudil high group, and the Fasudil low group were injected with iodixanol injections at a dosage of 4 gI/kg through caudal veins. Mice in the control group were injected with the same dosage of saline. Respectively at 12 h and 2 h before contrast agent injection and 4 h after contrast agent injection, mice in the two Fasudil groups were administered with Fasudil through intraperitoneal injections. The dosage for the Fasudil high group was 10 mg/kg, and the dosage for the Fasudil low group was 10 mg/kg. At the same time nodes, mice in the model group were administered with the same dosage of saline. The histopathological changes in renal tissues, the variations in renal functions, as well as the changes in renal hemodynamics, were observed. RESULTS Results: (1) Compared with the control group, in the model group, the serum creatinine (Cr) and blood urea nitrogen (BUN), as well as the urine N-acetyl-β-D-glucosaminidase (NAG) levels, increased significantly (P<0.05). Compared with the model group, in the Fasudil high group, the serum Cr and BUN, as well as the urine NAG levels, increased significantly (P<0.05). (2) After high-dose fasudil intervention treatment, the destruction of kidney structure in mice was significantly reduced, and the condition of renal tubular epithelial cells swelling was improved. (3) Compared with the control group, in the model group, the RABF values of mice decreased significantly (P<0.05). In the high Fasudil group, after the intervention of high dosed Fasudil, the RABF values of mice increased significantly (P<0.05). CONCLUSIONS Conclusion: The therapy of high-dosage Fasudil for acute renal damages of mice induced by contrast agents could effectively reduce the serum Cr, serum BUN, and urine NAG levels and act as an anti-apoptotic and anti-infective agent. In addition, Fasudil could resist the oxidative stress, thereby improving the contrast agent-induced vasoconstriction responses. The special functional imaging of SPECT can objectively reflect the function of living organs. CLINICALTRIAL

Sign in / Sign up

Export Citation Format

Share Document